Health Canada Gives Green Light to Tetra Bio-Pharma’s Cannabis Vs. Fentanyl Trial

ORLEANS, Ontario, Aug. 09, 2018 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that Health Canada has approved its protocol for a clinical trial investigating its PPP001 drug as an alternative to the opioid fentanyl in the management of breakthrough cancer pain.  The clinical trial will be conducted by Montreal-based Santé Cannabis, a medical clinic and contract research organization specialized in clinical research for cannabis – based therapies.

The trial will assess the time-to-relief in patients suffering from breakthrough cancer pain.  Based on its clinical data, Tetra believes that the pharmacodynamic properties of PPP001 may provide a novel faster acting alternative to the opioid fentanyl.  In addition, the time-to-maximal plasma concentrations of THC suggest that PPP001 will provide rapid relief to the patient’s suffering.  As a prescription drug with a Drug Identification Number

... read more at: https://markets.businessinsider.com/news/stocks/health-canada-gives-green-light-to-tetra-bio-pharma-s-cannabis-vs-fentanyl-trial-1027446396

by